ADGM (Adagio Medical Holdings) Research & Development: $9.72 Mil (TTM As of Mar. 2026)


ADGM Adagio Medical Holdings Inc ADGM
11 GF Score
Price $0.68
! 3 Warning Signs
View Full Analysis

What is Adagio Medical Holdings Research & Development?

Adagio Medical Holdings ADGM +5.30% 11 Research & Development is $9.72 Mil as of Mar. 2026. GuruFocus rates ADGM with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Adagio Medical Holdings's Research & Development for the three months ended in Mar. 2026 was $2.74 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $9.72 Mil.

Adagio Medical Holdings  (NAS:ADGM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Adagio Medical Holdings Research & Development Related Terms

Adagio Medical Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Adagio Medical Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagio Medical Holdings Research & Development Chart

Adagio Medical Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
15.36 17.86 15.40 0.00 10.64

Adagio Medical Holdings Quarterly Data
Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.66 1.97 2.77 2.24 2.74
ADGM
11GF Score
Adagio Medical Holdings Inc ADGM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagio Medical Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.72 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $9.72 Mil mean?
Adagio Medical Holdings (ADGM) has a Research & Development of $9.72 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Adagio Medical Holdings and its competitors.
Is Adagio Medical Holdings' Research & Development too high?
Adagio Medical Holdings' current Research & Development is $9.72 Mil. Overall, Adagio Medical Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Adagio Medical Holdings' Research & Development compare to VNRX and PMI?
Adagio Medical Holdings' Research & Development of $9.72 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Adagio Medical Holdings and its competitors. Adagio Medical Holdings's current Research & Development is $9.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagio Medical Holdings stock overvalued right now?
Adagio Medical Holdings (ADGM) has a current Research & Development of $9.72 Mil. The current Research & Development is $9.72 Mil. Adagio Medical Holdings' overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Adagio Medical Holdings (ADGM), the current Research & Development is $9.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adagio Medical Holdings Business Description

Address 26051 Merit Circle, Suite 102, Laguna Hills, CA, USA, 92653
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
11GF Score

Get the complete analysis for ADGM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.68
Price